Hubble Therapeutics, a Hanover, NH-based patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, raised $7.3M in Series A funding.
Backers were not disclosed.
The company intends to use the funds to advance its lead candidate, HUB-101, into human clinical trials.
Hubble Therapeutics is a patient-focused biotechnology company developing a new gene therapy for Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two debilitating retinal diseases that lead to severe vision loss in adult and pediatric patients. The company founds its work based on research from ProfessorĀ Bikash Pattnaik’sĀ lab at theĀ University of Wisconsin-MadisonĀ and Public Health and licensed from the Wisconsin Alumni Research Foundation (WARF).
To date, HUB-101 has received Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA for this program. It has partnered with Andelyn Biosciences inĀ Columbus, Ohio, and Virscio inĀ New Haven, Connecticut, to develop, manufacture, and conduct IND-enabling studies. Hubble Therapeutics expects to enter the clinic to conduct Phase I / II trials in 2026 to demonstrate the safety and efficacy of HUB-101.
FinSMEs
25/03/2025